- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01036490
Exercise in Obese Diabetic Patients With Chronic Kidney Disease (EX-ODCKD)
Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Panoramica dello studio
Descrizione dettagliata
Patients with type 2 diabetes, obesity, and chronic kidney disease (CKD) are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. However, there have been no randomized controlled trials to determine the benefits of exercise training in this population. This study seeks to substantiate the hypothesis that increasing energy expenditure by exercise training in the obese diabetic patient with CKD will result in the following benefits:
- Renal benefits, including reduction in proteinuria and stabilization of glomerular filtration rate (GFR)
- Cardiovascular benefits, including decreased blood pressure, decreased heart rate, and increased exercise tolerance.
- Improved glucose control (lower glycated hemoglobin), lipid control (decreased cholesterol with improved atherogenic profile)
- Improved body composition (weight loss, increased lean body mass and decreased fat mass).
- Decreased inflammation (assessed by high-sensitivity C-reactive protein), endothelial dysfunction (assessed by flow-mediated dilatation), and oxidative stress (assessed by reduced glutathione).
- Increased health-related quality of life.
In preparation for this proposal, the investigators performed a 24-week randomized controlled feasibility study comparing aerobic exercise plus optimal medical management to medical management alone in patients with type 2 diabetes, obesity (BMI > 30 kg/m2), and stage 2-4 CKD (eGFR 15-90 mL/min/1.73m2) with persistent proteinuria of > 200 mg/g. Subjects randomized to exercise underwent thrice weekly aerobic training for 6 followed by 18 weeks of supervised home exercise. The primary outcome variable was change in proteinuria. Exercise training resulted in a significant improvement in exercise duration during stress testing which persisted until 24 weeks. This was accompanied by significant decreases in resting systolic blood pressure and 24-hour proteinuria at 24 weeks. No changes were seen in the control group. The investigators concluded that exercise training in obese diabetic patients with CKD is feasible and results in a demonstrable training effect (increased exercise duration and decreased resting blood pressure). Moreover, it may decrease proteinuria and thus have a renoprotective effect.
The investigators now propose a larger-scale randomized controlled trial to determine the effects of exercise on renal functions, cardiovascular fitness, inflammation, and oxidative stress in diabetic patients with CKD. This will be a 52-week randomized study based on the investigators' pilot study design with some modifications. As opposed to the 6-week training period and 18-week home exercise period utilized in the pilot study, subjects randomized to exercise will undergo 12 weeks of intensive exercise training in the exercise laboratory followed by 40 weeks of supervised home exercise training (total duration of study 1 year). Moreover, due to recent recommendations that resistance training be incorporated into exercise training regimens in type 2 diabetic patients, the investigators will incorporate resistance (strength) training in this proposal. The primary outcome variable will be change in proteinuria at 12 and 52 weeks. Secondary outcome variables will be change in albuminuria and estimated glomerular filtration rate (eGFR) at 12 and 52 weeks. In addition, the investigators will measure blood pressure (BP), glycated hemoglobin, lipid profile, C-reactive protein (CRP) levels, body weight and composition, endothelial dysfunction (by flow-mediated dilatation), and Quality of Life (QoL) evaluations. The Index of Coexistent Diseases (ICED) to measure comorbidities to determine if comorbid conditions had any influence on the outcomes of the study. The Center for Epidemiologic Studies Depression Scale (CES-D) will also be used to determine the influence of depression (covariate) on study outcomes and adherence with the study objectives.
This study will directly address the effects of a structured exercise program in a patient population at high risk for cardiovascular complications. The investigators will specifically address the novel idea that exercise will not only improve cardiovascular fitness but will also ameliorate the renal complications resulting from diabetes.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Hines, Illinois, Stati Uniti, 60141-5000
- Edward Hines Jr. VA Hospital, Hines, IL
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Diabetes mellitus
- CKD Stages 2-4
- BMI > 30
- Persistent proteinuria (urine protein/creatinine > 200 mg/g for > 3 mo)
- On treatment with ACE inhibitor or ARB
- On treatment with aspirin
- On treatment with statin (if LDL > 100)
Exclusion Criteria:
- Symptomatic neuropathy/retinopathy
- Positive stress test due to coronary arterial disease
- Symptomatic cardiovascular disease
- Congestive heart failure (New York Heart Association Class III or IV)
- Chronic obstructive pulmonary disease (FEV1 < 50% predicted and/or requires supplemental oxygen support during exercise)
- Complaints of angina during the stress test
- Cerebrovascular disease/cognitive impairment
- Renal transplant
- Inability to walk on the treadmill
- Any unforeseen illness or disability that would preclude exercise testing or training
- Participation in a formal exercise program within the previous 12 weeks
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Controllo
Gruppo di controllo
|
|
|
Sperimentale: Exercise
Exercise Group
|
Exercise training for 12 weeks followed by home exercise for 40 weeks
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change in Proteinuria
Lasso di tempo: 12 weeks minus baseline
|
12 weeks minus baseline
|
|
Change in Proteinuria
Lasso di tempo: 52 weeks minus baseline
|
52 weeks minus baseline
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change in Albuminuria
Lasso di tempo: 12 weeks minus baseline
|
12 weeks minus baseline
|
|
Change in Albuminuria
Lasso di tempo: 52 weeks minus baseline
|
52 weeks minus baseline
|
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Lasso di tempo: 12 weeks minus baseline
|
12 weeks minus baseline
|
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Lasso di tempo: 52 weeks minus baseline
|
52 weeks minus baseline
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Eileen G. Collins, PhD RN, Edward Hines Jr. VA Hospital, Hines, IL
- Investigatore principale: David J Leehey, Edward Hines Jr. VA Hospital, Hines, IL
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- F7264-R
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Malattia renale cronica
-
Zhen LiIscrizione su invitoTrapianto simultaneo di pancreas-kidneyCina
-
University Hospital, Basel, SwitzerlandNon ancora reclutamentoSindrome cardiovascolare-kidney-metabolica | Sindrome cradiovascolare-kidney-metabolica (CKLM)Svizzera
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanNon ancora reclutamentoObesità Diabete mellito di tipo 2 | Malattia epatica steatotica associata a disfunzione metabolica | Sindrome cardiovascolare-kidney-metabolicaTaiwan
-
CHU de ReimsNon ancora reclutamentoReattività fluida nel periodo di trapianto post-kidney precoceFrancia
-
Third Affiliated Hospital, Sun Yat-Sen UniversityAttivo, non reclutanteInsufficienza epatica acuta su Chronic (ACLF)Cina
-
Camille N. Kotton, MDKamada, Ltd.; University of Texas Southwestern Medical CenterReclutamentoCitomegalovirus | Trapianto renale; Complicazioni | Trapianto d'organo | Complicanze del trapianto di fegato | Trapianto simultaneo di fegato-kidney; ComplicazioniStati Uniti
-
Yaqrit LtdKing's College Hospital NHS Trust; University College, London; Royal Free Hospital... e altri collaboratoriNon ancora reclutamentoCirrosi epatica | Insufficienza epatica acuta su Chronic (ACLF)
-
Nanjing Medical UniversityNon ancora reclutamentoSindrome cardiovascolare-kidney-metabolica
-
Institute of Liver and Biliary Sciences, IndiaNon ancora reclutamentoInsufficienza epatica acuta su Chronic (ACLF)
-
Institute of Liver and Biliary Sciences, IndiaNon ancora reclutamentoInsufficienza epatica acuta su Chronic (ACLF)